JPS6130559B2 - - Google Patents
Info
- Publication number
- JPS6130559B2 JPS6130559B2 JP10990478A JP10990478A JPS6130559B2 JP S6130559 B2 JPS6130559 B2 JP S6130559B2 JP 10990478 A JP10990478 A JP 10990478A JP 10990478 A JP10990478 A JP 10990478A JP S6130559 B2 JPS6130559 B2 JP S6130559B2
- Authority
- JP
- Japan
- Prior art keywords
- urine
- phenylalanyl
- amino
- kallikrein
- human urine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000002700 urine Anatomy 0.000 claims description 33
- 102000001399 Kallikrein Human genes 0.000 claims description 11
- 108060005987 Kallikrein Proteins 0.000 claims description 11
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000006911 enzymatic reaction Methods 0.000 claims description 8
- 108010039627 Aprotinin Proteins 0.000 claims description 6
- 229940108519 trasylol Drugs 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 3
- 238000002795 fluorescence method Methods 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- FARHNJDDPBXWES-UHFFFAOYSA-N 3-amino-4-methylchromen-2-one hydrochloride Chemical compound CC1=C(C(OC2=C1C=CC=C2)=O)[NH3+].[Cl-] FARHNJDDPBXWES-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000921 elemental analysis Methods 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 208000012904 Bartter disease Diseases 0.000 description 5
- 208000010062 Bartter syndrome Diseases 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010058188 Low-Molecular-Weight Kininogen Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- SJSSFUMSAFMFNM-NSHDSACASA-N (2s)-5-(diaminomethylideneamino)-2-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 SJSSFUMSAFMFNM-NSHDSACASA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 208000016998 Conn syndrome Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000057032 Tissue Kallikreins Human genes 0.000 description 1
- 108700022175 Tissue Kallikreins Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000013846 primary aldosteronism Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10990478A JPS5536759A (en) | 1978-09-07 | 1978-09-07 | Measuring method of kallikrein in human urine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10990478A JPS5536759A (en) | 1978-09-07 | 1978-09-07 | Measuring method of kallikrein in human urine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5536759A JPS5536759A (en) | 1980-03-14 |
| JPS6130559B2 true JPS6130559B2 (enrdf_load_stackoverflow) | 1986-07-14 |
Family
ID=14522095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10990478A Granted JPS5536759A (en) | 1978-09-07 | 1978-09-07 | Measuring method of kallikrein in human urine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5536759A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0382648A (ja) * | 1989-08-28 | 1991-04-08 | Michiharu Saji | オートマチックシートベルト |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4335203A (en) * | 1980-07-10 | 1982-06-15 | The Regents Of The University Of California | Method for identifying potential contrast media reactors |
| JPS5843798A (ja) * | 1981-09-09 | 1983-03-14 | Mamoru Sugiura | ヒト尿中カリクレインの活性測定用試薬 |
| US4515890A (en) * | 1982-11-08 | 1985-05-07 | Abbott Laboratories | Immunoassay of terminal deoxynucleotidyl transferase |
-
1978
- 1978-09-07 JP JP10990478A patent/JPS5536759A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0382648A (ja) * | 1989-08-28 | 1991-04-08 | Michiharu Saji | オートマチックシートベルト |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5536759A (en) | 1980-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH11302257A (ja) | 置換イソキノリン−３−カルボキサミド、その製法および薬剤としてのその使用 | |
| JPS61189298A (ja) | 新規オリゴペプチジルアルギニノール誘導体 | |
| JPS6366197A (ja) | 新規なペプチド誘導体 | |
| CN116947963A (zh) | 一种基于VHL配体靶向冠状病毒3CL蛋白酶的PROTACs及其制备方法与应用 | |
| HU201961B (en) | Process for producing 2,3-disubstituted isoxazolidines and pharmaceutical compositions comprising same | |
| DE2649171A1 (de) | Neue dipeptidderivate und deren salze, sowie verfahren zur messung der enzymaktivitaet unter verwendung dieser dipeptidderivate | |
| JPS6126558B2 (enrdf_load_stackoverflow) | ||
| US20220401419A1 (en) | Hydrogen peroxide-responsive keap1-nrf2 ppi inhibitor prodrug, and preparation method therefor | |
| JPS6130559B2 (enrdf_load_stackoverflow) | ||
| JPS5936611B2 (ja) | ペプチドの製造方法 | |
| DK145799B (da) | Tripeptider eller salte deraf til anvendelse som diagnostisk kromogent substrat med hoej specificitet overfor thrombin og thrombinlignende enzymer | |
| JPH10504283A (ja) | コレステロール分解酵素のラクタム阻害剤 | |
| JPH059068B2 (enrdf_load_stackoverflow) | ||
| JPS6112920B2 (enrdf_load_stackoverflow) | ||
| JPH0414120B2 (enrdf_load_stackoverflow) | ||
| JPS6027675B2 (ja) | ７−アルギニルアミノ−４−メチルクマリン | |
| JPS6342637B2 (enrdf_load_stackoverflow) | ||
| CN118406041A (zh) | 一种Tazemetostat的合成方法 | |
| JPS6337094B2 (enrdf_load_stackoverflow) | ||
| JPS5842862B2 (ja) | ペプチド誘導体 | |
| JPH0755942B2 (ja) | 酵素活性測定用ペプチド誘導体及びその使用法 | |
| JPH1180174A (ja) | インスリン様作用を有するバナジル錯体 | |
| CN116410251A (zh) | 一种成像肿瘤衰老的荧光/光声分子探针及其应用 | |
| JPS59222457A (ja) | ペプチド誘導体及びその用途 | |
| CN115477638A (zh) | 一种托匹司他的制备方法 |